Psoriasis

The AJMC® Psoriasis compendium is a comprehensive resource for clinical news and expert insights for the chronic skin disease, which tends to go through cycles where it flares and goes into remission.

Latest News

Medicines on shelf - Prasanth - stock.adobe.com.jpg
Rising Costs of Biologics for Plaque Psoriasis Highlight Savings Potential

April 24th 2025

Substantial savings opportunities exist by using lower-cost biologics for patients with plaque psoriasis, according to one study.

Plaque psoriasis | Image credit: Milan Lipowski - stock.adobe.com
Icotrokinra Shows Clear Skin in 75% of Adolescents With Plaque Psoriasis in Phase 3 Trial

April 10th 2025

Psoriasis oral treatment | Image credit: Pawel - stock.adobe.com
Women Have Lower Drug Survival With Biologics for Psoriasis, Including IL-17 and IL-23 Inhibitors

April 7th 2025

Psoriasis treatment concept | Sviatlana - stock.adobe.com
Tildrakizumab Effective Up to Nearly 3 Years Regardless of BSA Affected, Obesity

April 1st 2025

Bimekizumab | Image credit: luchschenF - stock.adobe.com
Bimekizumab Reduces Inflammation, Cardiovascular Risk

March 21st 2025

A Personalized Approach to Disease Management in Psoriasis

A panel of experts discuss their personalized approaches to treating patients with psoriasis and comorbidities such as metabolic syndrome.

Ryan Haumschild, PharmD, MS, MBA, Bhavesh Shah, PharmD, Mark Lebwohl, MD, and Robert Groves, MD.
Continuing Medical Education
View All
April 30th 2025

Treatment Gaps in the Management of Generalized Pustular Psoriasis: Enhancing the Role of Managed Care

1.5 Credits / Dermatology, Immunology
April 30th 2025

Advancing Patient Outcomes in Hidradenitis Suppurativa: Updates and Strategies for Managed Care

1.5 Credits / Dermatology

More News

Image of pneumonia
August 30th 2022

Psoriasis May Lower Pneumonia Risk in Patients With ESRD

Jaime Rosenberg
A decade’s worth of retrospective data from over 1 million patients with end-stage renal disease (ESRD) undergoing dialysis showed that psoriasis may be protective against pneumonia in these patients.
Patrick Burnett, MD, PhD, FAAD, chief medical officer of Arcutis Biotherapeutics.
August 25th 2022

Dr Patrick Burnett Explains Mechanism of Action for Roflumilast Cream in Psoriasis

Matthew Gavidia
Patrick Burnett, MD, PhD, FAAD, chief medical officer of Arcutis Biotherapeutics, discusses the mechanism of action for roflumilast cream, the only phosphodiesterase-4 inhibitor approved by the FDA for the treatment of plaque psoriasis in patients aged 12 and older.
graphic representing autoimmune disease
August 16th 2022

TNF Inhibitors Linked to Higher Risk of Psoriasis in Patients With IBD, RA

Jaime Rosenberg
While noting that providers and their patients should be aware of the potential risk, the researchers underscored that the risk of new-onset psoriasis due to tumor necrosis factor-α inhibitor (TNFi) treatment appears to be rare and that strategies do not need to change for patients with immune-mediated inflammatory diseases such as inflammatory bowel disease (IBD) and/or rheumatoid arthritis (RA).
Image of psoriasis
August 14th 2022

Study Suggests Causal Link Between Psoriasis, Cardiovascular Disease

Lindsey Mulrooney
The findings add to previous research on similar outcomes between psoriasis and cardiovascular disease, using a Mendelian randomization study.
Patrick Burnett, MD, PhD, FAAD.
August 13th 2022

Dr Patrick Burnett on Clinical Research Needs, Awareness of Intertriginous Psoriasis

Matthew Gavidia Alisha Lekh
Patrick Burnett, MD, PhD, FAAD, chief medical officer of Arcutis Biotherapeutics, discusses the need for increased research and awareness on intertriginous disease in psoriasis.
psoriasis image
August 10th 2022

Plaque Psoriasis Itching May Impact HRQOL Even if Condition Improves

Jaime Rosenberg
The real-life findings showed that treatment with brodalumab improved health-related quality of life (HRQOL) for patients but itching prevented complete improvement.
Clock showing time
August 3rd 2022

Asian Patients With Psoriasis Receive Shortest Visits With Dermatologists

Lindsey Mulrooney
Dermatologists spend less time face-to-face with Asian patients with psoriasis compared with patients of other races and ethnicities, despite Asian patients frequently experiencing more severe cases of psoriasis.
Patrick Burnett, MD, PhD, FAAD.
July 30th 2022

Dr Patrick Burnett Addresses Unmet Needs, Management Strategies in Psoriasis

Matthew Gavidia Alisha Lekh
Patrick Burnett, MD, PhD, FAAD, chief medical officer of Arcutis Biotherapeutics, speaks about disease manifestations, comorbidities, and other factors to consider in the management of psoriasis.
Image of psoriasis
July 25th 2022

Psoriasis Associated With Higher Risk of Organ-Based Comorbidities

Jaime Rosenberg
According to the investigator, these findings further support psoriasis as a systemic inflammatory disease.
Patrick Burnett, MD, PhD, FAAD, chief medical officer of Arcutis Biotherapeutics.
July 23rd 2022

Dr Patrick Burnett Discusses Risk Factors for Adverse Behavioral Health, QOL in Psoriasis

Matthew Gavidia Alisha Lekh
Patrick Burnett, MD, PhD, FAAD, chief medical officer of Arcutis Biotherapeutics, discussed key factors associated with poor behavioral health issues and quality of life among patients with psoriasis.
Hands of older person
July 21st 2022

Psoriasis, Psoriatic Arthritis Linked With Age, Earlier Birth Cohorts

Lindsey Mulrooney
Despite incidence of psoriasis decreasing, older populations in Taiwan have a higher risk of developing psoriasis and psoriatic arthritis, according to a recent study.
Patrick Burnett, MD, PhD, FAAD
July 14th 2022

Dr Patrick Burnett Reviews Patient Survey Findings on Unmet Needs in Psoriasis

Matthew Gavidia
Patrick Burnett, MD, PhD, FAAD, chief medical officer of Arcutis Biotherapeutics, discusses findings of a recent survey exploring the emotional burden of plaque psoriasis and unmet needs related to current topical treatments.
Biologic drug.
July 6th 2022

Drug Survival of Psoriasis Biologics Associated With Efficacy, Safety Profile

Matthew Gavidia
Drug survival rates of biologics in patients with psoriasis were shown to be associated with their effectiveness and safety profiles, in which incidence of psoriatic arthritis, nail involvement, and other factors were indicated as effect modifiers.
Doctor talking to patient
July 2nd 2022

Mendelian Randomization Study Suggests Causal Relationship Between IBD, Psoriasis

Julia Bonavitacola
A Mendelian randomization study found that there appears to be a causal relationship between inflammatory bowel disease (IBD) and psoriasis.
doctor holding needle
July 1st 2022

No Increased Risk of Severe COVID-19 Among Children With Psoriasis Using Biologics

Hayden E. Klein
Researchers found no evidence of increased risk for severe COVID-19 among children receiving biologic therapies for their psoriasis.
Heart stethoscope.
June 24th 2022

PsA Linked With Higher Prevalence of Cardiovascular Events, Risk Factors

Matthew Gavidia
Patients with psoriatic arthritis (PsA) exhibited a higher prevalence of cardiovascular risk factors and events vs the general population, including atherothrombotic disease.
Biologic use.
June 22nd 2022

Biologic Switching Patterns, Discontinuation in Psoriasis Investigated in New Study

Matthew Gavidia
An analysis of biologic drug use patterns in patients with psoriasis from Tuscany, Italy, associated etanercept with the highest frequency of switching to other biologics; secukinumab and ustekinumab were linked with the lowest risk.
Hand with psoriasis rash
June 18th 2022

Symptom Control, Skin Clearance Relevant Outcomes in Patients With Psoriasis

Julia Bonavitacola
A systematic review found that skin clearance, symptom control, and treatment safety were among the highest expected outcomes of treatment for patients with psoriasis.
Elderly man and woman.
June 15th 2022

Clinical Characteristics of Geriatric Psoriasis Vary by Age, Sex

Matthew Gavidia
Sex and age were associated with clinical characteristics of geriatric psoriasis, including type and location of disease, therapeutic considerations, and risk of comorbid nail involvement and psoriatic arthritis.
women and men.
June 6th 2022

Women Report Greater Psoriasis QOL Impact, Reduced Treatment Satisfaction With Biologics

Matthew Gavidia
Efficacy of biologics was observed in both men and women with psoriasis, although female patients reported a greater impact from the disease on quality of life (QOL) and lower treatment satisfaction.
Doctor and pregnant patient.
June 2nd 2022

Psoriasis May Increase Risk of Ectopic Pregnancy, a Driver of Maternal Morbidity

Matthew Gavidia
Risk of ectopic pregnancy, the leading cause of maternal morbidity and mortality in the first trimester of pregnancy, was significantly associated with psoriasis in Danish women, especially those with moderate to severe disease.
Liver assessment.
May 31st 2022

Study Finds Link Between Psoriasis, NAFLD Among US Adult Outpatients

Matthew Gavidia
US adult outpatients with psoriasis have a greater risk of developing nonalcoholic fatty liver disease compared with those without the skin condition.
Dcotor and patient.
May 28th 2022

Real-world Efficacy of Risankizumab in Psoriasis Shown for Patients With Prior Biologic Failure

Matthew Gavidia
Real-world patients with moderate to severe plaque psoriasis who had experienced prior biologic failure demonstrated significant improvement and an adequate safety profile with risankizumab treatment.
Physician examining patient palm.
May 18th 2022

Tildrakizumab Shows Clinical Improvement of Difficult-to-Treat Areas in Psoriasis

Matthew Gavidia
Real-world patients with psoriasis demonstrated significant improvement in difficult-to-treat scalp, nail, palmoplantar, and genital disease manifestations with the IL-23 inhibitor tildrakizumab.
health care.
May 16th 2022

Greater Biologic Persistence, Adherence Achieved With Ixekizumab for Psoriasis

Matthew Gavidia
Significantly greater persistence, adherence, and time on monotherapy was achieved with the use of ixekizumab vs the biologics adalimumab, etanercept, secukinumab, and ustekinumab, in the treatment of moderate to severe psoriasis.
Hand pain.
May 14th 2022

Greater Psoriatic Arthritis Activity, Impact Observed in Low-Income Countries

Matthew Gavidia
Patients with psoriatic disease who live in low-income countries exhibited the highest disease activity and impact despite similar usage of biologic drugs to that of higher-income areas.
Skin.
May 11th 2022

Study Finds Bimekizumab Well Tolerated Long Term for Moderate to Severe Psoriasis

Matthew Gavidia
Bimekizumab demonstrated a favorable long-term safety profile for the treatment of moderate to severe psoriasis, aside from an increased incidence of mild to moderate oral candidiasis that was also observed with short-term exposure.
Patient data.
May 5th 2022

Overlapping Comorbidity Risks Found in Patients With Plaque Psoriasis, Palmoplantar Pustulosis

Matthew Gavidia
An overlapping comorbidity profile was observed among patients with plaque psoriasis and palmoplantar pustulosis, although risks of certain comorbid conditions varied between the 2 groups.
Heart and stethoscope.
May 2nd 2022

Cardiovascular Risk Significantly Greater in Patients With Psoriatic Disease

Matthew Gavidia
A significantly greater risk of cardiovascular events was observed among a multiethnic Brazilian population of patients with psoriasis and psoriatic arthritis vs controls, in which those in the sixth decade of life had the highest risk.
Stephen Rozzo, PhD.
April 30th 2022

Dr Stephen Rozzo on Next Investigative Targets for Tildrakizumab in Psoriasis

Matthew Gavidia
Stephen Rozzo, PhD, associate vice president and head, Biologics Medical Affairs, Sun Pharma, North America, discussed next steps in the evaluation of tildrakizumab for the treatment of psoriasis.
<12345678910
...
15>

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo